Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Slit Face Trial Using Micro-injections of Transparent Hyaluronic Acid Gel for Rejuvenation of the Cheek

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02679924
Recruitment Status : Unknown
Verified February 2017 by Isabella Guiha, Goldman, Butterwick, Fitzpatrick and Groff.
Recruitment status was:  Active, not recruiting
First Posted : February 11, 2016
Last Update Posted : March 1, 2017
Sponsor:
Collaborator:
Galderma
Information provided by (Responsible Party):
Isabella Guiha, Goldman, Butterwick, Fitzpatrick and Groff

Brief Summary:
Soft tissue augmentation with injectable hyaluronic acid (HA) is a well-established modality for the correction of facial volume loss, fat atrophy, fine lines, and wrinkles. HA is a glycosaminoglycan that is composed of repeating D-glucuronic acid and D-N-acetylglucosamine disaccharide units. Because HA is a natural and inert constituent of the dermis, it represents an ideal substance for soft tissue augmentation. Current FDA-approved HA fillers are typically utilized to either directly target specific cutaneous rhytids or to restore overall contours by placement into fat pads or along bony structures that have remodeled with age. Restylane® Silk is a transparent injectable HA gel that received FDA approval in June 2014 for use in the lips and peri-oral region. Its unique synthesis results in smaller and finer particles that demonstrate significant hygroscopic properties and give rise to the potential for unique applications. One such application concerns the concept of "skin boosting" whereby microaliquots of HA are placed into the skin to induce biophysical improvement in dermal characteristics (1). Using this technique, a recent split-body study by Streker et al. demonstrated significant aesthetic improvements in face, hands and décolletage (2). However, there have been no well-controlled studies with validated aesthetic outcomes utilizing Restylane® Silk in this fashion to date. Because of the unique combination of ultra-fine product and high water-attracting capability, the investigators hypothesize that microinjections of Restylane® Silk can be used in a grid-like injection pattern for rejuvenation of the aging cheek.

Condition or disease Intervention/treatment Phase
Problem of Aging Device: Hyaluronic Acid filler Other: Sham Comparator Not Applicable

Detailed Description:
This is a single center, prospective, randomized, sham-controlled, double-blind, split-face trial using micro-injections of Restylane® Silk for correction of mid to low cheek fine lines and wrinkles. Twenty (20) subjects will be enrolled. Each subject will receive Restylane® Silk to a defined area of mid to low cheek in a randomized blinded fashion with the contralateral cheek treated by sham injection. The injections will be delivered intradermally 1mm in depth via multiple 0.02 cc microinjections distributed in a grid array pattern with 0.5 cm to 1 cm between each injection point over total treatment area. The sham injections will be administered in identical fashion and will consist of sterile normal saline. Following completion of injection treatment, manual massage will be applied to the full area to promote even distribution of the product. The maximum amount of Restylane Silk to be used per treatments session/per cheek for balancing treatment is1cc (not to exceed a total of 3cc) per treated patient. Three dimensional digital photography utilizing the Vectra 3D System (Canfield) will be utilized to document pre-treatment status, sites of injection, and post-treatment effect. Subjects will be followed up at 1 week, 2 week, 4 week, day 90, and day 180 time points. At the Day 180 time point, every subject will be given the option to receive touch up and balancing treatments to both cheeks.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Single Center, Prospective, Randomized, Sham Controlled, Double Blind, Split Face Trial Using Micro-injections of Transparent Hyaluronic Acid Gel (Restylane® Silk) for Rejuvenation of the Aging Cheek
Study Start Date : November 2015
Estimated Primary Completion Date : August 2017
Estimated Study Completion Date : September 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Restylane Silk
Micro-injections of Restylane® Silk Hyaluronic Acid filler for correction of mid to low cheek fine lines and wrinkles.
Device: Hyaluronic Acid filler
The objective of this study is to determine the efficacy and safety of Restylane® Silk Hyaluronic Acid filler microinjections when used in a grid-like injection pattern for the correction of fine lines to the cheeks.
Other Name: Restylane Silk

Sham Comparator: Sham Comparator
Micro-injections of normal saline for correction of mid to low cheek fine lines and wrinkles.
Other: Sham Comparator
Micro-injections of normal saline for correction of mid to low cheek fine lines and wrinkles.
Other Name: Normal Saline




Primary Outcome Measures :
  1. Change in Wrinkling and Elastosis [ Time Frame: month 6 ]
    Efficacy will be determined based on the difference between blinded evaluator assessment of Fitzpatrick-Goldman Classification of Wrinkling and Degree of Elastosis Scale between Baseline and Month 6.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Male or female in general good health age 18 or over.
  • Mild to moderate static rhytids involving at least a 9 cm2 area of the mid to low cheeks.
  • Must be willing to give and sign a HIPPA form, photo consent and informed consent form.
  • Must be willing to comply with study dosing and complete the entire course of the study.
  • Female patients will be either of non-childbearing potential defined as:

    1. Having no uterus
    2. No menses for at least 12 months
    3. Bilateral tubal ligation Or;

(WOCBP) women of childbearing potential must agree to use an effective method of birth control during the course of the study, such as:

  1. Oral contraceptive pill, injection, implant, patch, vaginal ring, intrauterine device
  2. Intrauterine coil
  3. Barrier method used with an additional form of contraception (e.g., sponge, spermicide or condom)
  4. Abstinence (If practicing abstinence must agree to use barrier method described above (3) if becomes sexually active).
  5. Vasectomized partner (must agree to use barrier method described above (3) if becomes sexually active with un-vasectomized).

    • Negative urine pregnancy test results Baseline prior to study entry (if applicable)

Exclusion Criteria:

  • Pregnant, planning pregnancy during the course of the study or breastfeeding
  • Severe static rhytids to the mid to low cheeks
  • Previous use of any form of soft tissue augmentation in the treatment area within the past 12 months
  • Pre-existing medical or dermatologic condition in the treatment area that may affect the treatment or interpretation of treatment effect (at investigator discretion)
  • Presence of tattoo and/or scar in the treatment area that in the investigators opinion would interfere with study assessments
  • Use of oral/topical retinoids within 1 month of Baseline
  • Previous use of botulinum toxins in the treatment area within the past 6 months
  • Previous surgical procedure in the treatment area within the past 12 months
  • Presence or evidence of any conditions that in the opinion of the investigator might impede the subject's ability to give consent or comply with protocol requirements.
  • Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study
  • History of non-compliance with clinical research protocols
  • Ablative laser resurfacing to on their face within 12 months
  • Non-ablative laser or light procedures to their face within the past 3 months
  • Known allergy to Restylane® Silk or any of its constituents

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02679924


Locations
Layout table for location information
United States, California
Dermatology Cosmetic Laser Medical Associates of La JOlla, Inc.
San Diego, California, United States, 92121
Sponsors and Collaborators
Isabella Guiha
Galderma
Investigators
Layout table for investigator information
Principal Investigator: Mitchel P Goldman, MD DCLA
Layout table for additonal information
Responsible Party: Isabella Guiha, Mitchel P. Goldman, MD (Principal Investigator), Goldman, Butterwick, Fitzpatrick and Groff
ClinicalTrials.gov Identifier: NCT02679924    
Other Study ID Numbers: RS-2015-01
First Posted: February 11, 2016    Key Record Dates
Last Update Posted: March 1, 2017
Last Verified: February 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Hyaluronic Acid
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Viscosupplements
Protective Agents